drugset / Trial / NCT04202978
Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation
Timeline
- Start
- 2020-03-01
- Primary completion
- 2021-03-01
- Completion
- 2021-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Capecitabine | Small molecule | 850 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |